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Abstract 
Background: Research has identified immunological abnormalities in Chronic Fatigue Syndrome/Myalgic Encepha‑
lomyelitis (CFS/ME), a heterogeneous illness with an unknown cause and absence of diagnostic test. There have been 
no CFS/ME studies examining innate and adaptive immune cells longitudinally in patients with varying severities. This 
is the first study to investigate immune cells over 6 months while also examining CFS/ME patients of varying symp‑
tom severity.
Methods: Participants were grouped into 18 healthy controls, 12 moderate and 12 severe CFS/ME patients and flow 
cytometry was used to examine cell parameters at 0 and 6 months.
Results: Over time, iNKT CD62L expression significantly increased in moderate CFS/ME patients and CD56bright NK 
receptors differed in severe CFS/ME. Naïve CD8+T cells, CD8−CD4− and CD56−CD16− iNKT phenotypes, γδ2T cells 
and effector memory subsets were significantly increased in severe CFS/ME patients at 6 months. Severe CFS/ME 
patients were significantly reduced in CD56brightCD16dim NKG2D, CD56dimCD16− KIR2DL2/DL3, CD94−CD11a− γδ1T 
cells and CD62L+CD11a− γδ1T cells at 6 months.
Conclusions: Severe CFS/ME patients differed from controls and moderate CFS/ME patients over time and expressed 
significant alterations in iNKT cell phenotypes, CD8+T cell markers, NK cell receptors and γδT cells at 6 months. This 
highlights the importance of further assessing these potential immune biomarkers longitudinally in both moderate 
and severe CFS/ME patients.
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Background
In the immune system, lymphocytes are subject to con-
tinual checkpoints, signals and regulation to allow 
successful cell development, homeostasis and to subse-
quently prevent illness [1]. Immune responses generated 
as a result of these signals between the innate and adap-
tive cells can fluctuate and have a critical influence on the 
maintenance of physiological homeostasis [1, 2]. Chronic 
Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) 
is a heterogeneous illness, varying in severity and nature 
of onset although research has consistently established 
immunological abnormalities [3–9].
Reduced Natural Killer (NK) cell cytotoxic activ-
ity is the most predominant and consistent outcome of 
immunological studies in CFS/ME. A number of param-
eters have also been shown to alter in patients, includ-
ing T regulatory cells (Tregs), iNKT cells, CD8+ T cells 
and cytokines [6, 8, 10]. Alterations in both innate and 
adaptive immune cells reflect the extent of immune 
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dysregulation in CFS/ME which may potentially be 
linked to the illness pathomechanism or contribute to 
future diagnostic methods.
Longitudinal studies of CFS/ME have also demon-
strated consistently reduced NK cell activity while there 
was variation in cytokine levels over time. It appears that 
longitudinal examination of immune cells in CFS/ME 
may allow an assessment of consistent immune param-
eters as potential biomarkers for the illness [2, 11]. This 
research further investigates immunological mark-
ers of the innate and adaptive immune system at 0 and 
6 months in moderate and severe CFS/ME patients.
Methods
Participants
This research was granted ethical approval after review 
by the Griffith University Human Research Ethics Com-
mittee (GU Ref No: MSC/23/12/HREC).
Participants previously recruited from Queensland 
and New South Wales areas of Australia were again 
approached for this follow-up study. All assessments 
were taken at 0 and 6 months. Participants were between 
20 and 65 years old and CFS/ME patients had the illness 
for a period of at least 6 months prior to the study. CFS/
ME was defined based on the 1994 Fukuda criteria in the 
absence of a biomarker or diagnostic test for the illness. 
CFS/ME patients were identified as either moderate or 
severe and these groups were confirmed using an exten-
sive questionnaire to assess symptomatology, health sta-
tus, quality of life, severity and mobility in all participants 
[10]. Participants were excluded if they were previously 
diagnosed with an autoimmune disorder, psychosis, heart 
disease or thyroid-related disorders or if they were preg-
nant, breast feeding, smoking, or experiencing symptoms 
of CFS/ME that did not conform to the Fukuda criteria 
for CFS/ME.
Participants (n =  42) in the follow up study included 
moderately (n =  12) or severely (n =  12) affected CFS/
ME patients as well as an age and sex matched non-
fatigued control group (n  =  18). The severe CFS/
ME group were housebound and the Fatigue Severity 
Scale (FSS), Dr Bell’s Disability Scale, the FibroFatigue 
Scale and the Karnofsky Performance Scale (KPS) were 
assessed in all participant groups as a determinant of 
severity [10, 12].
Sample preparation
A non-fasting blood sample of 50 mL was collected from 
the antecubital vein of participants into lithium heparin-
ised and ethylenediaminetetraacetic acid (EDTA) tubes. 
Blood was collected between 8:00 and 11:30 am and 
samples were analysed within 12  h of collection. Initial 
full blood count assessment was undertaken to determine 
levels of white blood cell and red blood cell markers.
Intracellular analysis
Density gradient centrifugation using Ficoll-hypaque 
(Sigma, St Louis, MO) was used to isolate PBMCs from 
EDTA whole blood. PBMCs were adjusted to 1  ×  107 
cells/mL and stained with monoclonal antibodies for T 
regulatory cell (Treg) phenotypes, NK lytic proteins and 
CD8 lytic proteins as described [4, 6] (Supplementary 
Table 1). The Treg phenotypes were assessed as PBMCs 
were permeablised and fixed with buffers containing 
diethylene glycol and formaldehyde before being stained 
with FOXP3. After washing with Phosphate Buffered 
Saline (PBS) (Gibco Biocult, Scotland), cells were ana-
lysed on the flow cytometer (Becton–Dickinson Immu-
nocytometry Systems) where the expression of FOXP3+ 
Tregs was determined on CD4+CD25+CD127low T cells 
[6]. NK and CD8 T cell lytic proteins were assessed as 
previously described [6]. Cells were incubated for 30 min 
in Cytofix then permwash was added. Perforin, granzyme 
A and granzyme B monoclonal antibodies were added to 
cells and incubated for 30 min in the dark at room tem-
perature. Cells were then washed and analysed on the 
flow cytometer where perforin, granzyme A and gran-
zyme B expression was measured in NK and CD8 T cells 
[6].
NK phenotype and receptors analysis
Natural killer cells were isolated from whole blood cells 
using a negative selection system RosetteSep Human 
Natural Killer Cell Enrichment Cocktail (StemCell Tech-
nologies, Vancouver, BC). Isolated NK cells were labelled 
with CD56, CD16, CD3 (BD Biosciences, San Diego, CA) 
and monoclonal antibodies for KIR receptors (Additional 
file 1: Table S1) (Miltenyi Biotec). Cells were analysed on 
the flow cytometer (Becton–Dickinson Immunocytom-
etry Systems) where NK cells were gated using CD56, 
CD16 and CD3 antibodies (Additional file  1: Table  S1) 
[4].
Whole blood analysis
Appropriate antibodies (Additional file 1: Table S1) were 
added to whole blood samples and incubated for 30 min. 
Following which cells were lysed, washed, fixed and 
analysed on the flow cytometer. iNKT, DC, B, γδ T and 
CD8+ T cell phenotypes were assessed using appropriate 
antibodies (Additional file 1: Table  S1) and gating strat-
egies on the flow cytometer (Additional file 1: Table S1) 
[13].
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Data and statistical analysis
All statistical analysis was performed using SPSS statis-
tical software version 22.0. Paired t tests were used to 
examine changes in each immune parameter between 0 
and 6 months for each of the groups. A one-way repeated 
measures analysis of variance (ANOVA) with time as a 
within-subject factor and group as a between-subject fac-
tor was used to assess the interaction of time and group. 
Results were classified as statistically significant at an 
alpha criterion of p < 0.05 if there were significant differ-
ences between groups over time.
The 6  month single time point analysis was assessed 
among the three participant groups (control, moder-
ate CFS/ME and severe CFS/ME) based on the distribu-
tion. If normally distributed, the analysis of variance test 
(ANOVA) was used. Shapiro–Wilk and Kruskal–Wal-
lis test of independent variables based on rank sums to 
determine the magnitudes of group differences was used 
if data was not normally distributed. The Bonferroni 
Post Hoc or Mann–Whitney U tests determined p val-
ues of significance for parametric and non-parametric 
data respectively, with statistical significance set at an 
alpha criterion at p  <  0.05. Clinical data are presented 
as mean ±  SD and immunological data are represented 
using mean  ±  SEM. Extreme outliers were identified 
using an SPSS boxplot and handled by eliminating par-
ticular data points from the analysis [14].
Results
Patient characteristics
The participant ages (mean  ±  SD) for the control 
(n = 18), moderate CFS/ME (n = 12) and severe CFS/ME 
(n = 12) patient groups were 41.94 ± 10.76, 44.73 ± 12.90 
and 41.27 ±  10.05 respectively, with no statistically sig-
nificant differences (p < 0.05) in age between the groups 
(Table 1). Gender distribution was also not significantly 
different between the groups as they were all predomi-
nantly female with control, moderate CFS/ME and severe 
CFS/ME groups having 72, 67 and 83  % female partici-
pants, respectively (Table 1).
All CFS/ME patients in the moderate and severe CFS/
ME groups satisfied the 1994 Fukuda criteria for CFS/
ME as those who did not were excluded from the study. 
According to the FibroFatigue Scale, all CFS/ME patients 
scored significantly worse than the control group except 
in relation to ‘sadness’ which had no differences in scores 
between any participant groups. There was no statisti-
cally significant difference between moderate and severe 
CFS/ME patients in the FibroFatigue Scales (data not 
shown). Dr Bells Disability scale (DRS) and the KPS were 
significantly different between all groups, with severe 
CFS/ME patients scores being further worsened signifi-
cantly compared to moderate CFS/ME (Fig. 1).
No change to intracellular parameters
There were no significant differences between any of the 
groups and between 0 and 6  months for Tregs, NK or 
CD8+ T cell lytic proteins.
No change to whole blood phenotypes
This research found no significant differences in DC or B 
cell phenotypes between any of the groups or between 0 
and 6 months.
iNKT cells
Between 0 and 6 months, iNKT cells expressing CD62L 
were significantly increased at 6  months in moderate 
CFS/ME patients (p = 0.004) (Fig. 2).
At the 6th month, CD8−CD4− and CD56−CD16− 
iNKT cells were significantly increased in severe CFS/ME 
compared to controls (p = 0.024 and 0.030) (Fig. 3).
KIRs
CD56brightCD16dim NK cells expressing KIR3DL1/DL2 
were significantly increased in controls and moderate 
CFS/ME patients after 6  months (p  <  0.000 and 0.004) 
(Fig. 4a). CD56brightCD16+ NK cells expressing KIR2DL1 
were significantly increased in severe CFS/ME patients 
after 6  months (p  =  0.011) (Fig.  4b). CD56brightCD16+ 
NK cells expressing KIR2DL2/DL3 were signifi-
cantly increased in controls and moderate CFS/ME 
patients after 6  months (p =  0.018 and 0.049) (Fig.  4c). 
CD56brightCD16+ NK cells expressing KIR2DS4 were also 
significantly increased in controls and moderate CFS/ME 
patients after 6 months (p = 0.038 and 0.023) (Fig. 4d).
At 6  months, CD56brightCD16dim NK cells express-
ing NKG2D were significantly reduced in severe CFS/
ME compared to moderate CFS/ME patients (p = 0.014) 
(Fig.  5a). Also at 6  months, KIR2DL2/DL3 expression 
in CD56dimCD16− NK cells was significantly reduced 
Table 1 Participant characteristics including age and gen-
der for control, moderate CFS/ME and severe CFS/ME par-
ticipant groups
Age data is represented as mean ± SD and gender is represented as percentage 
of group which that is female in control (n = 18), moderate CFS/ME (n = 12) and 
severe CFS/ME (n = 12) groups. There were no significant differences in age or 
gender within the research groups. CFS/ME Chronic Fatigue Syndrome/Myalgic 








Age in years 
(mean ± SD)
41.94 ± 10.76 44.73 ± 12.90 41.27 ± 10.05 0.540
Gender  
(% Female)
72 % 67 % 83 % 0.566
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in severe CFS/ME patients compared to controls 
(p = 0.045) (Fig. 5b).
CD8 T cells
At 6  months, naïve CD8 T cells were significantly 
increased in severe CFS/ME patients compared to mod-
erate CFS/ME patients (p = 0.041) (Fig. 6).
γδ T cells
At the 6  months, total γδ2 T cells were significantly 
increased in severe CFS/ME compared to controls 
and moderate CFS/ME patients (p  =  0.035 and 0.034) 
(Fig.  7a). At 6  months, γδ2 effector memory and 
CD45RA+ effector memory T cells were also significantly 
increased in the severe CFS/ME patient group compared 
Fig. 1 Average severity scale scores at 0 and 6 months for control, moderate and severe CFS/ME patients. a Dr Bells Disability Scale scores for each 
group, represented as a score between 0 and 100. b Karnofsky Performance Scale scores for each group, represented as a score between 0 and 100. 
All data is presented as mean ± SEM where statistical significance was accepted as p < 0.05. CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalo‑
myelitis, SEM standard error of the mean
Fig. 2 iNKT cell expression of CD62L in control, moderate and severe 
CFS/ME patients at 0 and 6 months. iNKT cells expressing CD62L as 
a percentage of total iNKT cells. Data is presented as mean ± SEM 
where statistical significance was accepted as p < 0.05. CFS/ME 
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard 
error of the mean
Fig. 3 iNKT cell expression profile in control, moderate and severe CFS/ME patients. a iNKT cells expressing a CD8−CD4− phenotype as a num‑
ber of total iNKT cells (cells/μL). b iNKT cells expressing a CD56−CD16− phenotype as a number of total iNKT cells (cells/μL). Data is shown as 
mean ± SEM where statistical significance was accepted as p < 0.05. CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard 
error of the mean
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to controls and moderate CFS/ME patients respectively 
(p = 0.003, 0.013 and 0.017, 0.032) (Fig. 7b, c).
At 6 months, γδ1 T cells in the severe CFS/ME group 
displayed significantly lower CD94−CD11a− expres-
sion when compared to the control and moderate CFS/
ME group (p = 0.018 and 0.047) (Fig. 8a). At 6 months, 
CD94−CD11a− expression in γδ2 T cells of severe CFS/
ME patients was significantly higher than controls and 
moderate CFS/ME (p =  0.019 and 0.005) (Fig.  8b). The 
severe CFS/ME group also had significantly higher 
CD94−CD11a+ expression on γδ2 T cells compared to 
controls (p = 0.025) in the 6 month (Fig. 8c).
At the 6th  month, γδ1 T cells expression of 
CD62L+CD11a− was significantly reduced in severe 
CFS/ME compared to both controls and moderate 
CFS/ME (p  =  0.013 and 0.023) (Fig.  8d). At 6  months, 
γδ2 T cells expression of CD62L+CD11a− as well as 
CD62L+CD11a+ was significantly increased in the severe 
CFS/ME group compared to controls and moderate CFS/
ME patients (p =  0.002, 0.001 and 0.045, 0.018 respec-
tively) (Fig. 8e, f ).
Discussion
The present study examined innate and adaptive immune 
cells at 0 and 6  months to investigate longitudinal 
changes in moderate and severe CFS/ME. Severe CFS/
ME patients displayed significant NK cell receptor differ-
ences over time when compared to controls and moder-
ate CFS/ME. At the 6th month, severe CFS/ME patients 
also demonstrated significant alterations in iNKT cell 
phenotypes, CD8+ T cell markers, NK cell receptors and 
γδ T cells compared with the control and/or moderate 
CFS/ME patients.
Our study demonstrated immunological variation 
over time as there were differences between participant 
groups between 0 and 6 months. iNKT cells had not pre-
viously been examined in CFS/ME and the current study 
found expression of CD62L was significantly increased 
in moderate CFS/ME patients between 0 and 6 months. 
The function of CD62L in iNKT cells is not known 
although this may suggest variation in iNKT cell mark-
ers or adhesion over time in CFS/ME. The CD56bright 
NK cell subset also varied between participant groups 
Fig. 4 Alterations in CD56bright NK cell receptors between 0 and 6 months in control, moderate and severe CFS/ME patients. a Percentage 
of CD56brightCD16dim NK cells expressing KIR3DL1/DL2. b Percentage of total CD56brightCD16+ NK cells expressing KIR2DL1. c Percentage of 
CD56brightCD16+ NK cells expressing KIR2DL2/DL3. d Percentage of CD56brightCD16+ NK cells expressing KIR2DS4. Data is shown as mean ± SEM 
where statistical significance was accepted as p < 0.05. NK Natural Killer, CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM stand‑
ard error of the mean
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over time, particularly in the severe CFS/ME patients. 
CD56brightCD16dim NK cells expressing KIR3DL1/DL2 
and CD56brightCD16+ NK cells expressing KIR2DS4 
and KIR2DL2/DL3 were significantly increased after 
6  months in controls and moderate CFS/ME patients, 
while severe CFS/ME patients showed significantly 
increased CD56brightCD16+ NK cells expressing the 
KIR2DL1 receptor after 6 months. This research showed 
changes in NK receptors over time notably in CD56bright 
NK cells. CD56bright NK cells form around 10 % of total 
peripheral NK cells and are the primary producers of NK 
cell-derived cytokines, particularly IFN-γ, TNF-β, mac-
rophage colony-stimulating factor (M-CSF), IL-10 and 
IL-13 during an innate immune response [15, 16]. Previ-
ously, peripheral levels of IL-10 and IFN-γ were shown 
to be significantly increased and longitudinal analysis 
has shown the CD56brightCD16− NK cell phenotype to 
be decreased over time in CFS/ME patients [2]. The cur-
rent study potentially suggests that the alterations in 
CD56bright NK cell subsets may be influencing cytokine 
production over time in CFS/ME. Cytokine imbalances 
between proinflammatory cytokines or cytokine inhibi-
tors may play a role in the initiation of a number of dis-
eases, particularly Th1/Th2 cytokine shifts which have 
been used to explain immunological disease pathogenesis 
[17].
Natural killer cell receptors are particularly important 
in CFS/ME as reduced NK cell cytotoxic activity is one 
of the most consistent markers of the illness [2–4, 6–8, 
10, 18]. NK cell cytotoxic activity can be regulated to by 
NKG2D, which is an activating receptor that has previ-
ously been significantly elevated in International Con-
sensus Criteria for CFS/ME-defined CFS/ME patients 
when compared to CFS/ME patients defined using the 
1994 Fukuda definition [5]. CD94 is a NK receptor which 
is dependent on NKG2 protein association and has also 
been significantly increased in CD56dimCD16− NK 
cells in CFS/ME patients in previous research [10]. Our 
study found significantly reduced NKG2D expression 
in CD56brightCD16dim NK cells in severe CFS/ME com-
pared to moderate CFS/ME at the 6th month. Therefore, 
reduced NKG2D may be associated with the reduced NK 
cell cytotoxic activity previously shown in severe CFS/
ME patients compared to moderate CFS/ME patients 
[4, 10]. Previous research has also suggested that impair-
ment of NK cell cytolytic function may be derived in part 
by reduced activating NK cell receptors, such as NKG2D 
[19].
KIR2DL2/DL3 is an inhibitory receptor that has been 
previously reduced in severe CFS/ME compared to mod-
erate CFS/ME patients [10]. The current study supports 
previous findings where KIR2DL2/DL3 expression in 
CD56dimCD16− NK cells in severe CFS/ME patients was 
again significantly reduced when compared to controls. 
Fig. 5 NK cell receptors in control, moderate and severe CFS/ME participant groups. a Percentage of total CD56brightCD16dim NK cells expressing 
the receptor NKG2D. b Percentage of total CD56dimCD16− NK cells expressing the receptor KIR2DL2/DL3. Data is shown as mean ± SEM where 
statistical significance was accepted as p < 0.05. NK Natural Killer, CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard error 
of the mean
Fig. 6 Increased naïve CD8+ T cells in the severe CFS/ME participant 
group. Number of total CD8+ T cells (cells/μL) of the naïve CD8+ T 
cell subset in controls, moderate CFS/ME and severe CFS/ME. Data is 
shown as mean ± SEM where statistical significance was accepted as 
p < 0.05. CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyeli‑
tis, SEM standard error of the mean
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This reduction in the inhibitory receptor of CFS/ME 
patients may be a result of a larger regulatory response 
to the reduced NK cell cytotoxic activity that is shown 
in the illness, particularly as CD56dim NK cells are highly 
cytotoxic [4, 15].
Significantly raised naïve CD8+ T cell numbers at the 
6th  month of this research in severe CFS/ME patients 
may be promoting the ability of these severely affected 
patients to develop an immune response against novel 
antigens and lower the susceptibility of infections [20]. 
CD8+ T cells are also responsible for cytotoxic activities 
and have previously shown significantly reduced activ-
ity in CFS/ME patients [6]. In contrast, CFS/ME patients 
have also previously been associated with CD8+ T cell 
immune activation, a reduced level of CD8+ suppressor 
T cells and an increase in CD8+ cytotoxic T cells [21]. 
Therefore the current study validates previous research 
where significantly enhanced CD8+ T cell activation and 
CD8+ T cell numbers were found in CFS/ME patients [8, 
21].
There is little research on iNKT cells in CFS/ME 
patients, although one study has shown significantly 
elevated iNKT cell numbers in severe CFS/ME patients, 
reduced CD8CD4, CD8aCD4 phenotypes in moderate 
CFS/ME, increased CD56CD16 and CCR7SLAM phe-
notypes in severe CFS/ME compared to both moderate 
CFS/ME patients and controls [10]. The present study 
again found significantly increased iNKT cells express-
ing CD56−CD16− in severe CFS/ME patients at the 
6th  month. The function of CD56 and CD16 on iNKT 
cells is unknown [13] however, altered expression of 
these markers on NK cell phenotypes is often shown in 
CFS/ME patients [3, 5, 6, 10, 21, 22]. The CD8− CD4− 
subset of iNKT cells is primarily responsible for cytotoxic 
activities and was previously reduced in moderate CFS/
ME patients [10]. The present study has shown a signifi-
cant increase in CD8− CD4− iNKT cells in severe CFS/
ME patients, suggesting a possible regulatory mechanism 
where cytotoxic activities may be enhanced in iNKT cells 
as a regulatory response to the reduced cytotoxic activity 
that has been consistently documented in NK cells and 
CD8+ T cells of CFS/ME patients [3, 4, 6, 8, 10].
The present study found significantly increased over-
all numbers of γδ2 T cells in severe CFS/ME at the 
6th month. As γδ T cells are sentinel cells with cytotoxic 
properties, this may suggest an activation as an immune 
response to bacterial infection, wound repair, antigen 
presentation or immunoregulation [23]. Significantly 
enhanced numbers of effector memory and CD45RA+ 
effector memory γδ2 T cells also in severe CFS/ME 
patients suggests that they have greater potential for 
cytotoxic activity, tissue homing and target recogni-
tion [10, 23]. Effector memory phenotypes of γδ T cells 
exhibit NK-like functions, detecting major histocom-
patibility complex (MHC) expression and undergoing 
cytotoxic activities following cytokine directed prolifera-
tion and regulatory pathways [23–25]. Interesting, both 
effector memory and CD45RA+ effector memory T cell 
phenotypes are preferentially mobilized during adren-
ergic stimulation, suggesting severe CFS/ME patients’ 
immune responses may be enhanced similar to a situa-
tion of psychological stress [23]. There may potentially be 
a homeostatic mechanism taking place in severe CFS/ME 
patients, leading to greater immune activation, similarly 
to that also shown in CD8+ T cells and Tregs in CFS/ME 
[2, 6, 7, 26].
CD94−CD11a− expression was significantly reduced in 
severe CFS/ME patients in γδ1 T cells and significantly 
increased in severe CFS/ME patients in γδ2 T cells. CD94 
Fig. 7 Alterations in γδ2 T cell phenotypes in control, moderate 
CFS/ME and severe CFS/ME patients. a Total number of γδ2 T cells 
expressed as total cells/μL. b Total number of γδ2 T cells (cells/μL) 
expressing the effector memory cell phenotype. c Total number of 
γδ2 T cells (cells/μL) expressing the CD45RA+ effector memory cell 
phenotype. Data is shown as mean ± SEM where statistical signifi‑
cance was accepted as p < 0.05. CFS/ME Chronic Fatigue Syndrome/
Myalgic Encephalomyelitis, SEM standard error of the mean
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is a surface molecule with NK-like abilities, important 
in MHC expression detection and high cytotoxic activi-
ties while CD11a is an adhesion molecule which aids 
migration to inflammatory sites [23]. γδ2 T cells express-
ing CD94−CD11a+ were also significantly increased in 
severe CFS/ME patients, suggesting that the majority 
of γδ T cells in these patients may have improved adhe-
sion and migration to sites of inflammation [23]. γδ1 
and γδ2 T cells also showed variation in CD62LCD11a 
expression, as severe CFS/ME patients demonstrated 
significantly reduced CD62L+CD11a− γδ1 T cells as well 
as significantly increased CD62L+CD11a− γδ2 T cells. 
CD62L+CD11a+ expression was increased in γδ2 T cells 
of severe CFS/ME patients, again potentially suggesting 
severe patients may have an enhanced immune activa-
tion and an increased adhesive and migratory ability 
compared to moderate CFS/ME and controls [23]. The 
alternative expression of these markers in γδ1 and γδ2 T 
cells may be a result of the differing γδ T cells phenotypes 
while γδ1 T cells are mainly present in epithelial tissues 
and low levels in the bloodstream and γδ2 T cells repre-
sent most of circulating γδ T cells [27].
Fig. 8 Profile of γδ1 and γδ2 T cell expression of receptors and adhesion molecules in control, moderate CFS/ME and severe CFS/ME patients. a 
γδ1 T cells with the expression CD94−CD11a−, as a number of total γδ1 T cells (cells/μL). b γδ2 T cells with the expression CD94−CD11a−, as a total 
number of γδ2 T cells (cells/μL). c γδ2 T cells with the expression CD94−CD11a+, as a total number of γδ2 T cells (cells/μL). d γδ1 T cells expressing 
CD62L+CD11a− as a total number of γδ1 T cells (cells/μL). e γδ2 T cells expressing CD62L+CD11a−, as a total number of γδ2 T cells (cells/μL). f γδ2 T 
cells with the expression CD62L+CD11a+, as a total number of γδ2 T cells (cells/μL). Data is shown as mean ± SEM where statistical significance was 
accepted as p < 0.05. CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard error of the mean
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Conclusions
This research was the first to assess innate and adaptive 
immune cells over time in moderate and severe CFS/
ME patients. Severe CFS/ME patients had significantly 
altered NK cell receptors over time in comparison to 
moderate CFS/ME patients and controls. Severe CFS/
ME patients also expressed significant changes in iNKT 
cell phenotypes, CD8+ T cell markers, NK cell receptors 
and γδ T cells compared to the control and/or moderate 
CFS/ME patients at 6 months. This research highlighted 
the importance of longitudinally assessing varying severi-
ties of CFS/ME patients to further examine variation in 
illness severity and consistency of potential immune 
abnormalities that have been shown. This research may 
also contribute to further understanding CFS/ME and 
potentially assist in leading to a diagnostic test based on 
distinct immunological markers.
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